Parathyroid hormone-related protein (PTHrp) expression in human bone metastases (BM)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 9696-9696 ◽  
Author(s):  
L. Costa ◽  
A. Fernandes ◽  
A. G. Oliveira ◽  
K. Leitzel ◽  
S. Ali ◽  
...  
2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 9696-9696
Author(s):  
L. Costa ◽  
A. Fernandes ◽  
A. G. Oliveira ◽  
K. Leitzel ◽  
S. Ali ◽  
...  

2006 ◽  
pp. 27-39
Author(s):  
Robert E. Coleman ◽  
T. J. Martin ◽  
Janine A. Danks ◽  
Michael A. Henderson

2000 ◽  
Vol 191 (2) ◽  
pp. 170-174 ◽  
Author(s):  
Julie Iddon ◽  
Nigel J. Bundred ◽  
Judith Hoyland ◽  
Sarah E. Downey ◽  
Pauline Baird ◽  
...  

1994 ◽  
Vol 101 (1-2) ◽  
pp. 295-306 ◽  
Author(s):  
Jane A. Glatz ◽  
Joan K. Heath ◽  
Justine Southby ◽  
Leonie M. O'Keeffe ◽  
Kiriyama Takeshi ◽  
...  

2007 ◽  
Vol 24 (2) ◽  
pp. 107-119 ◽  
Author(s):  
Xiyun Deng ◽  
Sarah H. Tannehill-Gregg ◽  
Murali V. P. Nadella ◽  
Guangchun He ◽  
Andrea Levine ◽  
...  

2005 ◽  
Vol 12 (3) ◽  
pp. 549-583 ◽  
Author(s):  
G A Clines ◽  
T A Guise

Calcium homeostasis is a tightly regulated process involving the co-ordinated efforts of the skeleton, kidney, parathyroid glands and intestine. Neoplasms can alter this homeostasis indirectly through the production of endocrine factors resulting in humoral hypercalcaemia of malignancy. Relatively common with breast and lung cancer, this paraneoplastic condition is most often due to tumour production of parathyroid hormone-related protein and ensuing increased osteoclastic bone resorption. Although control of hypercalcaemia is generally successful, the development of this complication is associated with a poor prognosis. The metastasis of tumour cells to bone represents another skeletal complication of malignancy. As explained in the ‘seed and soil’ hypothesis, bone represents a fertile ground for cancer cells to flourish. The molecular mechanisms of this mutually beneficial relationship between bone and cancer cells are beginning to be understood. In the case of osteolytic bone disease, tumour-produced parathyroid hormone-related protein stimulates osteoclasts that in turn secrete tumour-activating transforming growth factor-β that further stimulates local cancer cells. This ‘vicious cycle’ of bone metastases represents reciprocal bone/cancer cellular signals that likely modulate osteoblastic bone metastatic lesions as well. The development of targeted therapies to either block initial cancer cell chemotaxis, invasion and adhesion or to break the ‘vicious cycle’ is dependent on a more complete understanding of bone metastases. Although bisphosphonates delay progression of skeletal metastases, it is clear that more effective therapies are needed. Cancer-associated bone morbidity remains a major public health problem, and to improve therapy and prevention it is important to understand the pathophysiology of the effects of cancer on bone. This review will detail scientific advances regarding this area.


2003 ◽  
Vol 284 (4) ◽  
pp. R1021-R1030 ◽  
Author(s):  
Janet L. Funk ◽  
Elton Migliati ◽  
Guanjie Chen ◽  
Hongbing Wei ◽  
Jonathan Wilson ◽  
...  

Parathyroid hormone-related protein (PTHrP) is a multifunctional peptide that enhances blood flow in non-central nervous system (CNS) vascular beds by causing vasodilation. PTHrP expression is induced in non-CNS organs in response to ischemia. Experiments were therefore undertaken to determine whether PTHrP can be induced in brain in response to ischemic injury and whether PTHrP can act locally as a vasodilator in the cerebral vasculature, an effect that could be neuroprotective in the setting of stroke. PTHrP expression was examined by Northern analysis and immunohistochemical staining in male Sprague-Dawley rats subjected to permanent middle cerebral artery occlusion (MCAO). Vasodilatory effects of superfused PTHrP(1–34) on pial arterioles were determined by intravital fluorescence microscopy. Effects of PTHrP(1–34) peptide administration on MCAO infarction size reduction were assessed. PTHrP expression was induced in the ischemic hemisphere as early as 4 h after MCAO and remained elevated for up to 24 h. Increased immunoreactive PTHrP at sites of ischemic tissue injury was located in the cerebral microvessels. Superfusion with PTHrP(1–34) peptide for up to 25 min increased pial arteriolar diameter by 30% in normal animals. In animals with permanent MCAO, PTHrP(1–34) peptide treatment significantly decreased cortical infarct size (−47%). In summary, PTHrP expression increases at sites of ischemic brain injury in the cerebrovasculature. This local increase in PTHrP could be an adaptive response that enhances blood flow to the ischemic brain, thus limiting cell injury.


Sign in / Sign up

Export Citation Format

Share Document